Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARCT-2303

Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Arcturus Therapeutics

Phase 3 Most advanced trial (none active)
ARCT Developer
1 Registered trials

What is ARCT-2303?

ARCT-2303 is a self-amplifying RNA vaccine encoding the Omicron XBB.1.5 variant of the SARS-CoV-2 spike antigen, intended to induce an immune response against COVID-19. It is being studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Therapy area
Infectious disease
Developer
Arcturus Therapeutics, Inc. (ARCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06279871 Phase 3 COVID-19 Completed ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Arcturus Therapeutics

ARCT-021 Phase 2 ARCT-032 Phase 2 ARCT-154 Phase 2/3 ARCT-165 Phase 1/2 ARCT-2138 Phase 1 ARCT-2304 Phase 1/2 ARCT-810 Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.

Follow ARCT, the company behind ARCT-2303

See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.